Latest Financial Performance News

Gale Pacific’s FY25 results show resilience amid tariff challenges, with strategic manufacturing diversification and brand refresh underway to drive future growth.

Emeco Holdings has refinanced its long-term debt with a new A$355 million facility, extending maturity and improving terms to support future growth.

CD Private Equity Fund III reported a $3.02 million net loss for the half-year ending September 2025, driven largely by foreign currency translation losses, yet maintained a 10 cent per unit distribution supported by portfolio realisations and cash management.

CD Private Equity Fund II reported a reduced net loss of $2.43 million for the half-year to September 2025, supported by $9.45 million in distributions from portfolio realisations. Despite foreign exchange headwinds, the Fund maintains a diversified portfolio and a positive long-term return track record.

CD Private Equity Fund I reported a $2.6 million net loss for the half-year ended 30 September 2025, driven by foreign exchange impacts and fair value adjustments, while distributing 8 cents per unit amid ongoing portfolio realisations.

Vysarn Limited has reported record FY25 profits and is aiming for a 33% NPBT increase in FY26, driven by acquisitions and progress on the Kariyarra Water Scheme. The company is expanding its national footprint amid growing water demand in mining and infrastructure sectors.

Joyce Group reported solid FY25 results with strong revenue growth and a 20% expansion in KWB showrooms, alongside a key leadership transition at KWB.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Swift Networks reports solid FY25 results with $17.7 million revenue and launches its next-generation Swift TV platform, backed by a recent $1.6 million capital raise and pre-orders across key sectors.

SomnoMed Limited reported a robust FY25 with revenue surpassing guidance and a landmark FDA clearance for its Rest Assure® oral device, setting the stage for sustained growth in oral appliance therapy.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.